|

BGB-16673 Clinical Trials

6 actively recruiting trials across 3 locations

Pipeline

Phase 3: 3Phase 1/2: 3

Top Sponsors

  • BeOne Medicines5
  • BeiGene1

Indications

  • Cancer6
  • Chronic Lymphocytic Leukemia4
  • B-cell Malignancy3
  • Small Lymphocytic Lymphoma3
  • Waldenström Macroglobulinemia2

Other2 trials

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Phase 3
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2

Phoenix, Arizona2 trials

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic Phoenix

Phase 3
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Birmingham, Alabama1 trial

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

University of Alabama At Birmingham Hospital

Phase 1/2

Jonesboro, Arkansas1 trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

St Bernards Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.